Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

C. Sessa, A. Perotti, C. Noberasco, F. De Braud, E. Gallerani, S. Cresta, M. Zucchetti, L. Viganò, A. Locatelli, J. Jimeno, J. W. Feilchenfeldt, M. D'Incalci, G. Capri, N. Ielmini, L. Gianni

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours. Feasibility and anti-tumour activity of T+D administered every 3 weeks were evaluated in 38 patients (STS=29, ABC=9) untreated for advanced disease. D was given at 60 mg/m2 and T at escalating doses from 600 to 800 μg/m2, which was the maximum tolerated dose due to dose-limiting febrile neutropenia and asthenia. The recommended dose - given to 18 patients in total - was 700 μg/m2 T with 60 mg/m2 D. The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients. The most common toxicities included a severe but reversible ASAT/ALAT increase (94%), nausea/vomiting, neutropenia, asthenia/fatigue, stomatitis. Partial response and stable disease were assessed in 18% and 56% of STS patients and in 55% and 33% of ABC patients. No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support further development of T+D.

Original languageEnglish
Pages (from-to)1153-1161
Number of pages9
JournalEuropean Journal of Cancer
Volume45
Issue number7
DOIs
Publication statusPublished - May 2009

Fingerprint

trabectedin
Sarcoma
Doxorubicin
Pharmacokinetics
Breast Neoplasms
Asthenia
Neoplasms
Febrile Neutropenia
Stomatitis
Maximum Tolerated Dose
Neutropenia
Nausea
Vomiting
Fatigue
Clinical Studies

Keywords

  • Breast cancer
  • Combination
  • Doxorubicin
  • Phase I
  • Soft tissue sarcoma
  • Trabectedin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. / Sessa, C.; Perotti, A.; Noberasco, C.; De Braud, F.; Gallerani, E.; Cresta, S.; Zucchetti, M.; Viganò, L.; Locatelli, A.; Jimeno, J.; Feilchenfeldt, J. W.; D'Incalci, M.; Capri, G.; Ielmini, N.; Gianni, L.

In: European Journal of Cancer, Vol. 45, No. 7, 05.2009, p. 1153-1161.

Research output: Contribution to journalArticle

Sessa, C. ; Perotti, A. ; Noberasco, C. ; De Braud, F. ; Gallerani, E. ; Cresta, S. ; Zucchetti, M. ; Viganò, L. ; Locatelli, A. ; Jimeno, J. ; Feilchenfeldt, J. W. ; D'Incalci, M. ; Capri, G. ; Ielmini, N. ; Gianni, L. / Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. In: European Journal of Cancer. 2009 ; Vol. 45, No. 7. pp. 1153-1161.
@article{5d778c53ebdb4e3db0e6ddbb7011db69,
title = "Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer",
abstract = "The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours. Feasibility and anti-tumour activity of T+D administered every 3 weeks were evaluated in 38 patients (STS=29, ABC=9) untreated for advanced disease. D was given at 60 mg/m2 and T at escalating doses from 600 to 800 μg/m2, which was the maximum tolerated dose due to dose-limiting febrile neutropenia and asthenia. The recommended dose - given to 18 patients in total - was 700 μg/m2 T with 60 mg/m2 D. The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients. The most common toxicities included a severe but reversible ASAT/ALAT increase (94{\%}), nausea/vomiting, neutropenia, asthenia/fatigue, stomatitis. Partial response and stable disease were assessed in 18{\%} and 56{\%} of STS patients and in 55{\%} and 33{\%} of ABC patients. No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support further development of T+D.",
keywords = "Breast cancer, Combination, Doxorubicin, Phase I, Soft tissue sarcoma, Trabectedin",
author = "C. Sessa and A. Perotti and C. Noberasco and {De Braud}, F. and E. Gallerani and S. Cresta and M. Zucchetti and L. Vigan{\`o} and A. Locatelli and J. Jimeno and Feilchenfeldt, {J. W.} and M. D'Incalci and G. Capri and N. Ielmini and L. Gianni",
year = "2009",
month = "5",
doi = "10.1016/j.ejca.2008.11.019",
language = "English",
volume = "45",
pages = "1153--1161",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

AU - Sessa, C.

AU - Perotti, A.

AU - Noberasco, C.

AU - De Braud, F.

AU - Gallerani, E.

AU - Cresta, S.

AU - Zucchetti, M.

AU - Viganò, L.

AU - Locatelli, A.

AU - Jimeno, J.

AU - Feilchenfeldt, J. W.

AU - D'Incalci, M.

AU - Capri, G.

AU - Ielmini, N.

AU - Gianni, L.

PY - 2009/5

Y1 - 2009/5

N2 - The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours. Feasibility and anti-tumour activity of T+D administered every 3 weeks were evaluated in 38 patients (STS=29, ABC=9) untreated for advanced disease. D was given at 60 mg/m2 and T at escalating doses from 600 to 800 μg/m2, which was the maximum tolerated dose due to dose-limiting febrile neutropenia and asthenia. The recommended dose - given to 18 patients in total - was 700 μg/m2 T with 60 mg/m2 D. The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients. The most common toxicities included a severe but reversible ASAT/ALAT increase (94%), nausea/vomiting, neutropenia, asthenia/fatigue, stomatitis. Partial response and stable disease were assessed in 18% and 56% of STS patients and in 55% and 33% of ABC patients. No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support further development of T+D.

AB - The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours. Feasibility and anti-tumour activity of T+D administered every 3 weeks were evaluated in 38 patients (STS=29, ABC=9) untreated for advanced disease. D was given at 60 mg/m2 and T at escalating doses from 600 to 800 μg/m2, which was the maximum tolerated dose due to dose-limiting febrile neutropenia and asthenia. The recommended dose - given to 18 patients in total - was 700 μg/m2 T with 60 mg/m2 D. The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients. The most common toxicities included a severe but reversible ASAT/ALAT increase (94%), nausea/vomiting, neutropenia, asthenia/fatigue, stomatitis. Partial response and stable disease were assessed in 18% and 56% of STS patients and in 55% and 33% of ABC patients. No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support further development of T+D.

KW - Breast cancer

KW - Combination

KW - Doxorubicin

KW - Phase I

KW - Soft tissue sarcoma

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=64449085620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64449085620&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.11.019

DO - 10.1016/j.ejca.2008.11.019

M3 - Article

C2 - 19114300

AN - SCOPUS:64449085620

VL - 45

SP - 1153

EP - 1161

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -